Hyperactivity and impulsiveness: difficulty in waiting for his turn, restlessness, difficulty to remain seated, excessive talking
ADHD, attention deficit hyperactivity disorder; OCD, obsessive–compulsive disorder .
A mental status examination was conducted according to the AMDP System ( 17 ). The patient was oriented with regard to time, place, person, and situation. He was friendly and cooperative in personal contact. In motor activity, he demonstrated restlessness (fidgeting with the legs, playing with the fingers, and partly increased body tension). He described his mood as slightly dysphoric; his affect was broad. He showed no evidence of delusions, hallucinations, or ideas of reference, but he had poor impulse control, attention deficits with quick distractibility, as well as concentration and short-term memory problems. The thought process was lightly circumstantial, but apart from that without a pathological finding. He did not display any sleep or eating disorders. Any kind of suicidal ideations were denied. The patient demonstrated insight into his mental disorder and was motivated for therapy. These aspects were also confirmed by a senior psychiatrist.
In further exploration, the patient stated that he had been suffering from an OCD since about the age of 10. At that time, a classmate had had an eye tumor, and in this context, he had first developed a washing compulsion for which a first presentation to a psychiatrist had taken place. Later on, he showed compulsive behavior in the form of compulsive counting and ritualized touching things and obsessive thoughts (fear of aliens and the special meaning of the color “blue”). These obsessions began after he watched a film about aliens as a teenager, which frightened him enormously although he does not believe in aliens. Overall, obsessive and compulsive symptoms have been affecting his life in many ways, but especially his work life, disrupting his functionality. He had been treated as an inpatient and outpatient several times, yet the OCD symptoms would still occupy 3–4 h per day (see Table 1 ). In addition, ambulatory psychotherapy (anamnestically cognitive behavioral therapy) had only helped him to a limited extent. However, the existing concentration problems were described as independent of obsessive–compulsive disorder. The current medication at the first visit consisted of paroxetine 30 mg/day and quetiapine 100 mg/day.
The patient also reported that, in the past, he had been drinking a lot of alcohol to compensate for his compulsions and impulsiveness. However, alcohol had disinhibited him in parts even more, and it had come to physical confrontations several times. He had lost control in situations in which he felt provoked. In the past, criminal proceedings had also been brought against him in this context. In the course of time, he developed an alcohol addiction. At the time of the first visit to our outpatient clinic, he had been completely abstinent from alcohol for 6 years. Drug consumption was also negated, which could also be confirmed by a toxicological screen at the inpatient admission.
The following information was gathered on the past psychiatric history: a first inpatient treatment because of the OCD (ICD-10: F42.2) took place in 2006. During that time, a suspected diagnosis of paranoid schizophrenia (ICD-10: F20.0) was made and treatment with risperidone 1.5 mg/day, olanzapine 10 mg/day, and lorazepam 1 mg/day was started. Risperidone was discontinued due to akathisia, and the patient was then treated with olanzapine 10 mg/day and paroxetine 20 mg/day. In 2008, the patient was treated in a day clinic for 1.5 months, where an OCD (ICD-10: F42.2) and an immature personality accentuation were diagnosed. During this treatment, the dose of sulpride was increased from 200 to 400 mg/day, which was prescribed during the outpatient treatment. Subsequently, sulpride was switched to paroxetine 60 mg/day. In 2009, the patient was hospitalized again due to worsening of the OCD symptoms. In 2012, an alcohol withdrawal treatment was completed. The discharge medication consisted of paroxetine 60 mg/day and olanzapine 10 mg/day. The diagnoses then consisted of alcohol dependence (ICD-10: F10.2), alcohol withdrawal syndrome (ICD-10: F10.3), OCD (ICD-10: F42.2), personality accentuation (ICD-10: F60.9), and an unspecified form of schizophrenia (ICD-10: F20.8). In 2013, another alcohol withdrawal treatment due to a relapse followed. Since then, he has been abstinent of alcohol according to his own statement. Discharge medication consisted of paroxetine 60 mg/day and promethazine 25 mg as needed. Since 2015, the patient has been undergoing an outpatient behavioral therapy treatment, without achieving complete remission of the OCD so far.
While there were no relevant diseases in the medical anamnesis, the family history revealed that his mother had been diagnosed with schizophrenia and his father had a history of alcohol addiction.
After the initial presentation in our outpatient clinic (December 2017), detailed diagnostic tests were performed, including the Diagnostic Interview for ADHD in adults (DIVA) and ADHD-specific questionnaires [Conners Adult ADHD Rating Scales (CAARS)—Self-Report: Long Version ( 18 ), Wender Utah Rating Scale (WURS), and Adult ADHD—Self-Report Scale (ADHD-SB)] as well as other questionnaires (e.g., Personality Styles and Disorder Inventory). The subjective assessment of ADHD-relevant symptoms was clearly significant in terms of inattention and hyperactivity, as well as temperament, affective instability, emotional overreaction, and impulsiveness. The CAARS revealed an ADHD index in percentile rank of 88, a DSM-IV Inattentive symptom scale in percentile rank of 98, a DSM-IV Hyperactive–Impulsive scale in percentile rank of 86, and a DSM-IV ADHD Symptoms Total in percentile rank of 96 (see Table 2 ). Available school reports were also reviewed: in primary school reports, the patient was described as an eager and endeavored student, who was partly distracted and showed fluctuations in cooperation with other students. A somewhat unfriendly behavior toward classmates was also reported. These descriptions were in accordance with the self-report of the patient and indicate the presence of ADHD in childhood. The available findings as well as the biographical and current anamnesis strongly suggested the diagnosis of ADHD in adulthood.
The patient's scores on CAARS (in percentile rank) and Y-BOCS.
Diagnostic stage, before ADHD-specific treatment (medication: paroxetine and quetiapine) | DSM-I = 98 DSM-Hy/I = 86 DSM-Total = 96 ADHD-Index = 88 | Symptom Checklist: Obsessions: 7/Compulsions: 7 Severity scale: Obsessions: 8/Compulsions: 10 |
At the end of the first inpatient treatment (medication: ER MPH and sertraline) | DSM-I = 10 DSM-Hy/I = 14 DSM-Total = 10 ADHD-Index = 5 | Symptom checklist: Obsessions: 1/Compulsions: 1 Severity scale: Obsessions: 5/Compulsions: 2 |
During the second inpatient treatment (medication: sertraline, quetiapine, onset of ER MPH treatment after 14 days of atomoxetine intake) | DSM-I = 54 DSM-Hy/I = 82 DSM-Total = 69 ADHD-Index = 76 | Symptom checklist: Obsessions: 4/Compulsions: 4 Severity scale: Obsessions: 11/Compulsions: 9 |
After discharge from second inpatient treatment (medication: ER MPH, sertraline and quetiapine) | DSM-I = 38 DSM-Hy/I = 35 DSM-Total = 35 ADHD-Index = 42 | Symptom checklist: Obsessions: 2/Compulsions: 4 Severity scale: Obsessions: 10/Compulsions: 8 |
ADHD, attention deficit hyperactivity disorder; ER MPH, extended-release methylphenidate; CAARS, Conners adult ADHD rating scales; DSM-I, DSM-IV inattentive symptoms; DSM-Hy/I, DSM-IV hyperactive–impulsive symptoms; DSM-Total, DSM-IV ADHD symptoms total; Y-BOCS, yale–brown obsessive compulsive scale .
Due to the complex comorbidity of psychiatric illnesses, the patient was admitted to our inpatient unit in January 2018 for medication adjustment. At that time, the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) ( 19 ) was performed to assess the severity of the OCD symptoms. Concerning the last 7 days, the patient affirmed seven out of 37 typical obsessive thoughts and seven of 21 typical compulsive behaviors. In the severity rating, the patient reached a total score of 18 points, of which eight points were scored in the obsessive thoughts scale and 10 points were on the compulsive behavior scale. The laboratory tests showed a mild folic acid deficiency, which was substituted accordingly. Electrocardiography, electroencephalography, as well as magnetic resonance imaging of the brain showed no abnormal findings.
In accordance with existing literature, we switched the medication from paroxetine 30 mg to sertraline 50 mg/day because of the lack of therapy response to paroxetine treatment for many years ( 20 , 21 ). A psychostimulant treatment with extended-release methylphenidate (ER MPH) was initiated. ER MPH was gradually dosed up to 30 mg/day. Under this medication, not only the ADHD symptoms but also his OCD symptoms improved, so that sertraline could subsequently be reduced to 25 mg/day. At this time, the patient stated that his OCD had almost completely disappeared and that the time he spent with obsessive thoughts and compulsive actions had decreased severely. Furthermore, he felt more balanced and reported that he did not get into conflicts so quickly anymore. As the restlessness decreased, quetiapine could also be reduced and eventually stopped.
One day before discharge (after 42 days on board), Y-BOCS and CAARS were applied again. The patient reported observing one out of 37 typical obsessive thoughts and one of 21 typical compulsive behaviors in the last 7 days. In the severity rating, the patient reached a total score of seven points (five points for obsessive thoughts and two points for compulsive behavior). The CAARS resulted in an ADHD index in percentile rank of 5, a DSM-IV Inattentive symptom scale in percentile rank of 10, a DSM-IV Hyperactive–Impulsive symptom scale in percentile rank of 14, and a DSM-IV ADHD Symptoms Total in percentile rank of 10 (see Table 2 ). The medication at discharge consisted of ER MPH 30 mg/day and sertraline 25 mg/day.
After discharge, the patient attended our ADHD outpatient clinic for regular follow-ups. On his first visit (1 day after the discharge), he reported a good response to the medical therapy with ER MPH and assured that he did not notice any side effects. He expressed the wish to increase the sertraline dose from 25 to 37.5 mg/day. In the following visit after 26 days, the patient reported unspecific anxiety and panic attacks and claimed to have reduced ER MPH to 10 mg on his own responsibility after having read the package leaflet and worrying about potential side effects. Thus, the remaining medication consisted of sertraline 50 mg/day and quetiapine 25 mg/day, which he started again without a consultation with our outpatient clinic.
In March 2018, a month later after the discharge, a second inpatient admission was initiated after an emergency contact of the patient with the ward. He described an increase in obsessive–compulsive symptoms and restlessness and reported that he suffered from panic attacks and sleep disorders and that he lost his appetite. The patient observed severe mood swings and distrust toward other people. The medication at administration consisted of ER MPH 10 mg/day, sertraline 37.5 mg/day, and quetiapine 25 mg as needed. However, he reported that he did not want to continue to take ER MPH. Therefore, therapy with atomoxetine was started as ER MPH was discontinued. Due to the worsened symptomatology, the sertraline dose was increased to 150 mg/day and quetiapine was dosed up to 125 mg/day. However, the OCD symptoms worsened further after the discontinuation of ER MPH despite increasing the doses of sertraline and quetiapine. After weighing up the symptoms before and after treatment with ER MPH, we decided together with the patient to restart the treatment with ER MPH. Physical well-being and a reduction of the OCD and ADHD symptoms were described after switching the medication from atomoxetine to ER MPH. On the first day of the switch, we performed Y-BOCS and CAARS again. For the last 7 days, the patient reported observing four of 37 typical obsessive thoughts and four of 21 typical compulsive behaviors. In the severity rating, the patient reached a total score of 20 points, of which 11 points were on the scale of obsessive thoughts and nine points were on the scale of compulsive behavior. The CAARS showed an ADHD Index in percentile rank of 76, a DSM-IV Inattentive symptom scale in percentile rank of 54, a DSM-IV Hyperactive–Impulsive scale in percentile rank of 82, and a DSM-IV ADHD Symptoms Total in percentile rank of 69 (see Table 2 ).
An improvement of compulsive thoughts and joyfulness was observed when sertraline was added. The patient was discharged in April 2018 (after 27 days on board) into outpatient care at the ADHS outpatient clinic. Five days after discharge, CAARS and Y-BOCS were performed again: the patient reported observing two of 37 typical obsessive thoughts and four of 21 typical compulsive behaviors within the last 7 days. In the severity rating, the patient reached a total score of 18 points, of which 10 points were on the scale of obsessive thoughts and 8 points were on the scale of compulsive behavior. The CAARS revealed an ADHD Index in percentile rank of 42, a DSM-IV Inattentive symptom scale in percentile rank of 38, a DSM-IV Hyperactive–Impulsive scale in percentile rank of 35, and a DSM-IV ADHD Symptoms Total in percentile rank of 35 (see Table 2 ). Discharge medication consisted of ER MPH 10 mg/day, quetiapine 125 mg/day, and sertraline 200 mg per/day. A timeline of this case presentation is shown in Figure 1 .
Timeline of events and medication.
In this case report, we present a case of successful treatment with psychostimulants in an adult patient with ADHD and comorbid OCD. Due to the late diagnosis of ADHD (in addition to an apparent misdiagnosis of schizophrenia and personality disorder), no effective treatment was initiated in his early life, resulting in an impacted quality of life up to now. After diagnosing ADHD, we treated the patient with ER MPH in addition to antidepressants for OCD treatment and observed that the adjunctive use of ER MPH resulted in enhanced treatment response. Contrary to reports in the literature, treatment with a stimulant did not cause a worsening of the OCD symptoms. Rather, the patient reported a severe decrease in OCD symptoms, which was also observable by the treatment team. A second administration was necessary due to a worsening of the OCD and ADHD symptoms occurring after the patient had reduced the dose of ER MPH on his own, because he was worried about side effects, which he had never actually experienced during the inpatient treatment. This case highlights the importance of frequent reassessment of comorbid conditions in the case of low treatment response to serotonin reuptake inhibitors and psychotherapy in patients with OCD. Untreated ADHD as a comorbid condition to OCD may reduce the treatment response on the OCD, as shown in previous studies ( 22 ).
Recognizing ADHD and OCD comorbidity is important for the clinical course of these disorders considering that the onset of OCD is significantly higher in adults with childhood ADHD symptoms and that the comorbidity is associated with more severe OCD symptoms and their persistence ( 23 , 24 ). Despite the increasing awareness and interest in ADHD, many affected adults are still underdiagnosed and untreated ( 25 ). The overlap of ADHD symptoms with several other psychiatric disorders, including mood disorders, substance abuse, and anxiety, and the high incidence of comorbid psychiatric conditions are probable reasons for the high number of missed ADHD diagnoses in adults ( 1 , 4 ).
On the basis of neuroimaging findings, structural and functional abnormalities in ADHD and OCD have been reported ( 26 ). A shared dysfunction in the mesial frontal cortex has been shown in patients with ADHD and OCD. On the other hand, disorder-specific dysfunctions were found in the caudate, cingulate, and parietal brain regions in patients with ADHD and in the lateral prefrontal cortex in OCD patients ( 27 ). Furthermore, fronto-striatal hypoactivity was observed in ADHD, whereas OCD shows fronto-striatal hyperactivity, which is also associated positively with symptom severity ( 10 ). Regarding structural abnormalities, a recent meta-analysis reported that patients with OCD have larger insular–striatal regions, whereas patients with ADHS have smaller ventrolateral prefrontal/insular–striatal regions ( 28 ). Nonetheless, apart from these disorder-specific abnormalities, both disorders show a similar neuropsychological impairment in executive functions.
Despite the high prevalence of OCD and ADHD comorbidity, only a few reports on the treatment of this comorbidity exist. Most of these studies were performed in child and adolescent populations, and as far as we know, only one was conducted in an adult population ( 14 ). Some of the case reports described obsessive–compulsive symptoms as a side effect of MPH treatment in patients with ADHD ( 12 – 14 , 29 – 32 ). However, a few studies also described a decrease of the obsessive–compulsive symptoms with MPH treatment ( 15 , 16 ). The latter results are in line with our findings. Still, there are no longitudinal and clinical controlled trials investigating the effect of MPH on the treatment of ADHD and OCD comorbidity. Although this case presentation is the first published report of a positive effect of ER MPH for the treatment of ADHD and OCD comorbidity in an adult patient, it also has certain limitations. This case report describes only one patient and a psychostimulant treatment with ER MPH in addition to the therapy with sertraline and quetiapine instead of a monotherapy. Also, it cannot be determined whether the patient took his medication regularly as prescribed after the first discharge.
The present case report highlights that treatment with psychostimulants in addition to a serotonin reuptake inhibitor can improve the obsessive–compulsive symptoms as well as the ADHD-specific symptoms in patients with ADHD and OCD comorbidity. Still, the treatment of this comorbidity remains challenging. Underdetection, misdiagnosis, as well as delay in the diagnosis of this comorbidity may cause a reduction in quality of life and low treatment response. Treating both disorders concurrently may help to decrease the symptom severity of both conditions. Monitoring the progress may also support the treatment process, allowing improvement of the treatment compliance as well as observing side effects. Yet, longitudinal and clinical controlled trials are needed to gain more information about the treatment of this comorbidity and to observe the treatment response longitudinally.
Ethics statement.
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
ED-S and MS were the main authors of the manuscript. ED-S performed the literature research on the comorbidity of ADHD and OCD. Both authors participated substantially in the writing and editing of the final manuscript.
MS has received speaker fees from Lilly, Medice Arzneimitte Pütter GmbH & Co. KG and Servier and was an advisory board member for Shire/Takeda. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We acknowledge support from the German Research Foundation (DFG) and Leipzig University within the program of Open Access Publishing. We thank Tina Stibbe for her English editing.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.649833/full#supplementary-material
IMAGES
VIDEO
COMMENTS
Background Paediatric obsessive-compulsive disorder (OCD) is a chronic condition often associated with severe disruptions of family functioning, impairment of peer relationships and academic performance. Mean age of onset of juvenile OCD is 10.3 years; however, reports on young children with OCD show that the disorder can manifest itself at an earlier age. Both an earlier age of onset and a ...
Obsessive-compulsive disorder (OCD) is a clinically heterogeneous disorder with many possible subtypes.[] The lifetime prevalence of OCD is around 2-3%.[] Evidence points to a bimodal distribution of the age of onset, with studies of juvenile OCD finding a mean age at onset of around 10 years, and adult OCD studies finding a mean age at onset of 21 years.[2,3] Treatment is often delayed in ...
There seems to be a bimodal distribution of age of onset of OCD, with one peak in preadolescent childhood and another in adulthood. Another distinction between child and adult OCD is gender representation. Whereas adult studies report either gender equality or a slight female predilection, paediatric clinical samples are clearly predominantly male.
The objective of this study is to enhance knowledge about the clinical presentation, diagnosis and possible treatment of OCD in very young children. Case presentation: We describe a prospective 6 month follow-up of five cases of OCD in very young children (between 4 and 5 years old). At the moment of first presentation, all children were so ...
However, when an index case is a child, that is, an pediatric case, ... Family-based treatment of early childhood obsessive-compulsive disorder: the pediatric obsessive-compulsive disorder treatment study for young children (POTS Jr)—a randomized clinical trial.
The present study provides preliminary data on childhood-onset OCD among children and adolescents and points to the need for larger community-based studies. View Show abstract
This case study illustrates the use of cognitive-behavioral therapy (CBT) for a 10-year-old girl with obsessive-compulsive disorder (OCD). Exposure and response prevention (ERP) is a form of CBT that involves facing feared triggers over an extended period of time without any rituals.
Obsessive-compulsive disorder (OCD) is defined for both children and adults in the DSM-IV-TR as follows: (APA, 2000, p. 462) "Either obsessions or compulsions," with obsessions consisting of recurrent and intrusive thoughts, images or impulses experienced as unwanted or distressing, and compulsions being repetitive behaviours that the person feels driven to do, usually with the aim of ...
Cognitive-behavioral therapy (CBT) remains one of the most effective treatments for obsessive-compulsive disorder (OCD). In this update of a previous article (), we define CBT, review the evidence for the efficacy of CBT for OCD, provide a case example and sample treatment plans, and discuss family factors that affect treatment outcome.In addition, we discuss group and family-based modalities ...
This case study therefore describes an intensive 2- or 3-session treatment of childhood OCD (e.g., Farrell et al., 2016) to improve efficient and rapid delivery of evidence-based treatment. The case of Sarah illustrates this intensive treatment model and highlights clinical considerations for therapists when delivery a concentrated, time ...
Cognitive-behavioral therapy (CBT) using exposure with response prevention (ERP) is the treatment of choice for obsessive-compulsive disorder (OCD); however, developmental modifications should be considered when treating young children. This article presents a case study illustrating family-based CBT using ERP with a 7-year-old boy.
Case Study of an Adolescent Boy with Obsessive Compulsive Disorder Susan S. Woods, Ph. D. Youth Services, Department of Psychiatry, University of Michigan P.Q. is a boy from Ohio, thirteen years, nine months of age. He was admitted to Children's Psychiatric Hospital on an emergency basis on 28 March 1975. He had been noted […]
Studies over the past decades note that OCD is variably found in 1% to 4% of persons (children, adolescents, adults) throughout the world often with a seriously negative impact on their lives; approximately 4 in 10 with OCD develop it as a chronic condition, and many seek to conceal their OCD from others (31-38).
Results. Twenty-four studies were included in this systematic review. Most studies used OCD samples (k = 16), with a few studies using a sample comprising of a range of psychiatric disorders (k = 6) and some studies using a general community sample (k = 2).Overall, there was support for a significant relationship between childhood trauma and OCS severity (8 out of 16 of the studies using OCD ...
This case study illustrates the use of cognitive-behavioral therapy (CBT) for a 10-year-old girl with obsessive-compulsive disorder (OCD). Exposure and response prevention (ERP) is a form of CBT that involves facing feared triggers over an extended period of time without any rituals. Research demonstrates that ERP is a highly effective treatment for children and adolescents with OCD.
Obsessive-compulsive disorder (OCD) in children and adolescents is a prevalent condition with a number of adverse correlates and implications. The cognitive-behavioral treatment of an 11-year-old girl with prolonged tooth brushing is described in this case study. The frequency of the
Although youth and adults with obsessive-compulsive disorder (OCD) endorse elevated incidence of exposure to traumatic life events during childhood, the existing literature on adverse childhood experiences (ACEs) and OCD is mixed and studies focusing on pediatric OCD are limited. The present study examines the relationship between ACEs and OCD onset, symptom severity, negative cognitive ...
Abstract. Obsessive-compulsive disorder (OCD) is generally believed to follow a chronic waxing and waning course. The onset of illness has a bimodal peak - in early adolescence and in early adulthood. Consultation and initiation of treatment are often delayed for several years. Studies over the past 2-3 decades have found that the long ...
The case of an adolescent girl (aged 15 years) who presented with significant levels of health anxiety and OCD is described. An adult cognitive behavioral model of health anxiety was adapted and integrated with evidence-based cognitive behavioral therapy (CBT) for children and adolescents with OCD.
Cognitive-behavioral therapy (CBT) is an effective treatment for childhood obsessive-compulsive disorder (OCD). However, no case studies of children younger than 7 years old have been published. This case report describes a 5-year-old boy with severe OCD. Treatment consisted of parent- and teacher-d …
On the one hand, our findings contradict results of another study showing more childhood traumatic experiences among treatment resistant OCD patients versus treatment responders ... Relationship between childhood sexual abuse and obsessive-compulsive disorder: Case control study. Israel Journal of Psychiatry and Related Sciences, 45 (3), 177-182.
Comorbid psychiatric conditions often complicate the treatment of childhood obsessive-compulsive disorder (OCD). Behavioral treatment of OCD using exposure plus response prevention for a boy with disruptive behavior disorders and two previous unsuccessful medication trials is described. ... Case study: behavioral treatment of obsessive ...
To our knowledge, there have been only a few studies, mostly case reports and case studies, reporting on the pharmacotherapy of this comorbidity. Some of these reports have shown that the use of stimulants may cause obsessive-compulsive symptoms as side effects ( 12 - 14 ), while others have reported a decline of OCD symptoms under ...